What amino acids are in BPC 157?

BPC-157 is a synthetic peptide made from 15 amino acids in this order: glycine, glutamic acid, proline, proline, proline, glycine, lysine, proline, alanine, aspartic acid, aspartic acid, alanine, glycine, leucine, and valine. The abbreviated sequence is Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val.

“Synthetic” means made rather than taken directly from the body. BPC-157 is based on part of a protein reported in human gastric juice. It is not itself an established naturally circulating human peptide. Its name expands to Body Protection Compound, but a name does not establish a protective effect in people. The 2025 research review places its proposed repair effects in a largely preclinical record: research conducted before reliable treatment evidence in people.

A gastric-ulcer study in rats reported smaller ulcers and faster healing with BPC-157. The researchers compared routes of administration, and delivery into muscle performed better than delivery into the stomach in that model. That is an animal result under experimental conditions, not a recommendation about a route for people.

The gastric origin can create an impression that the peptide’s behavior throughout the body is already understood. A separate study in rats and dogs found rapid breakdown and an elimination half-life under 30 minutes. Half-life describes how quickly an amount falls by half. Stability in gastric fluid and persistence in blood are different properties. Neither finding supplies a human treatment schedule.

Angiogenesis means the formation of new blood vessels. In a study of VEGFR2 signaling, BPC-157 promoted vessel formation in chick membrane models, rats, and cultured human vascular cells. VEGFR2 is a receptor involved in vessel growth. The researchers also observed improved blood-flow recovery in a rat model with impaired circulation.

These findings offer a possible explanation for repair effects seen in experimental tissues. The human cells were in a dish; this was not a treatment trial in people. Evidence of a pathway also cannot show how a tendon injury will feel, how well a person will move, or what risks may emerge with repeated exposure. Those require their own clinical studies.

A small intravenous safety pilot involved two healthy adults. It reported no adverse events or measurable changes in the safety markers assessed. That is a narrow observation in two people, not evidence that uncommon harms are absent or that BPC-157 heals an injury.

The 2025 narrative review described only three human pilot studies and a lack of rigorous large trials. It also noted how much foundational research came from one group and the need for broader replication. Replication means another research team testing whether a finding holds up. The human evidence cannot support the confidence often attached to repair claims.

Long-term human safety remains unresolved. Pregnancy, breastfeeding, and pediatric safety have not been established. Blood-vessel growth raises a theoretical concern in active or suspected cancer because tumors also depend on a blood supply. This concern comes from the experimental mechanism; it is not a demonstrated human cancer outcome.

People in research-use communities report easier movement and less stiffness, as well as redness, headaches, stomach upset, and fatigue. These are anecdotes, not clinical evidence, and cannot establish how often a benefit or harm occurs. Research-labeled material also leaves questions about identity, purity, and sterility that a published study cannot resolve.

BPC-157 has no FDA-approved medical use. In the FDA record dated April 22, 2026, BPC-157’s nomination is marked withdrawn. That is not approval for compounding or clearance of FDA’s safety concerns. A compounded medicine is not FDA-approved. The sequence can be described precisely while the clinical benefit and risk remain uncertain.

A clinical discussion can distinguish a diagnosis, an experimental mechanism, and a treatment claim. Which outcome was actually measured? Was the work done in people? Was there a comparison group? Those questions matter more than the certainty of a chemical name.

The comparison page shows why BPC-157 animal research cannot be read as equivalent to semaglutide’s large human trials. The questions page addresses related claims about names, ingredients, and safety.